Azenta sale of B Medical Systems delayed as buyer fails to secure financing
The planned sale of B Medical Systems by Azenta has been delayed because the buyer, Thelema, failed to secure the necessary financing by the March 31, 2026 deadline. Although the transaction did not close, the sale agreement has not been amended or terminated, and both parties are evaluating potential paths forward as Thelema continues its financing efforts. The completion of the sale remains uncertain.
Azenta (NASDAQ: AZTA) faces delay in B Medical Systems sale as buyer financing lags
Azenta Inc. (NASDAQ: AZTA) announced that the sale of its B Medical Systems S.À R.L. subsidiary to Thelema S.À R.L. did not close by the expected March 31, 2026 deadline. The delay is due to Thelema not yet securing the necessary financing for the transaction, which remains subject to all closing conditions. Azenta is evaluating future steps, and there is no guarantee the deal will close on a revised timeline or at all.
Azenta Faces Delay in B Medical Systems Divestiture
Azenta's planned sale of its subsidiary B Medical Systems to Thelema did not close by the March 31, 2026 deadline because Thelema failed to secure the necessary financing. While the transaction agreement remains intact, Azenta (AZTA) is exploring its options as Thelema continues its efforts to obtain funding, creating uncertainty for stakeholders. Analysts currently rate AZTA as a Hold with a $21.00 price target, and TipRanks' AI Analyst, Spark, assesses it as Neutral due to strong financial flexibility offset by weak technical momentum and profitability pressures.
Allspring Global Investments Holdings LLC Raises Position in Azenta, Inc. $AZTA
Allspring Global Investments Holdings LLC has increased its stake in Azenta, Inc. (NASDAQ:AZTA) by 7.8% during the fourth quarter, now owning 1,388,047 shares valued at $46.35 million. This reflects increased institutional interest in Azenta, which also announced a $250 million share repurchase program, suggesting management views the stock as undervalued. Despite missing recent EPS estimates and trading below its average analyst target, 99.08% of the stock is held by hedge funds and institutional investors.
Azenta Inc (AZTA) Stock Price Quote Today & Current Price Chart
This page provides the current stock price quote and chart for Azenta Inc (AZTA). It is a basic stock information page for investors.
Azenta, Inc. (NASDAQ:AZTA) Receives Average Recommendation of "Hold" from Analysts
Azenta, Inc. (NASDAQ:AZTA) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $41.33. The company recently missed EPS expectations but saw revenue increase by 0.8% year-over-year. Shares are currently trading around $21.31, and Azenta's board authorized a $250 million share repurchase plan, indicating management believes the stock is undervalued.
Vanguard realigns reporting; subsidiaries to report AZTA holdings separately (AZTA)
Vanguard has filed an amendment to its Schedule 13G/A, reporting 0 shares beneficially owned in Azenta Inc. This change follows an internal realignment effective January 12, 2026, which disaggregated certain Vanguard subsidiaries' holdings. Consequently, these subsidiaries will now report their holdings separately, and Vanguard states it no longer beneficially owns the securities held by these entities.
Azenta: Life Science Player Fails To Come To Life (NASDAQ:AZTA)
Azenta, Inc. (AZTA) shares have fallen to new lows around $20, despite its operating assets being valued at just 0.5x sales and a substantial net cash position of approximately $600 million. Recent developments include the acquisition of UK Biocentre and the divestiture of B Medical Systems, which is expected to remove an earnings drag. The company maintains its full-year guidance, with the author viewing the stock as a compelling buy due to low expectations, significant liquidity, and underappreciated asset value, despite above-average risks.
Congress Asset Management Co. Invests $42.76 Million in Azenta, Inc. $AZTA
Congress Asset Management Co. has invested $42.76 million in Azenta, Inc. (NASDAQ:AZTA) by purchasing over 1.28 million shares. This new stake represents approximately 2.80% ownership in the company. Azenta has also authorized a $250 million stock repurchase program, signaling management's belief that the stock may be undervalued, despite recently missing EPS expectations and posting modest year-over-year revenue growth.
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
Azenta, Inc. (Nasdaq: AZTA), a leading provider of life sciences solutions, announced its participation in the Raymond James 47th Annual Institutional Investor Conference. Company management will present on Tuesday, March 3rd, 2026, at 4:00 p.m. ET, with a live webcast and replay available on their investor relations website. The company specializes in cold-chain sample management and multiomics services for the pharmaceutical, biotech, academic, and healthcare sectors.
Azenta's (AZTA) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC has reiterated its "buy" rating for Azenta (NASDAQ:AZTA) with a $44.00 target price, suggesting a 110.43% potential upside. This comes amidst varied opinions from other analysts, resulting in an average "Hold" rating for the company with a consensus target price of $41.33. Azenta recently reported Q4 earnings, missing consensus estimates but showing a year-over-year revenue increase, and announced a $250 million share repurchase plan.
Needham Reiterates Buy Rating on Azenta (AZTA) with Price Target of $44 | AZTA Stock News
Needham has reiterated its Buy rating for Azenta (AZTA) and maintained a $44 price target, signaling a continued positive outlook for the company's stock. This decision follows a history of varying analyst ratings and price target adjustments for Azenta, a provider of biological and chemical sample exploration and management solutions. Wall Street analysts project an average target price of $37.71 for AZTA, implying an 80.36% upside from its current price, while GuruFocus estimates a fair value of $72.74, suggesting a 247.87% upside.
Azenta Details UK Biocentre Buyout to Expand Europe Biobanking, Near-Term EBITDA Dilution Seen
Azenta has acquired UK Biocentre for GBP 20.5 million to expand its European biobanking operations and scale its biorepository services. This acquisition is expected to result in a near-term Adjusted EBITDA dilution of approximately 35 basis points in FY26 but is anticipated to become accretive in 2027 and 2028, driven by revenue synergies and increased operational leverage. UK Biocentre, which has a storage capacity of over 30 million samples, will continue to operate under its existing brand and identity, aiming to leverage government programs, expand pharma/biotech sales, and integrate with Azenta’s other European sites.
Azenta stock hits 52-week low at $22.44
Azenta Inc. (AZTA) reached a 52-week low of $22.44, representing a 43.92% decline over the past year amidst market volatility and company-specific challenges. Despite this, InvestingPro analysis suggests the stock is undervalued and in oversold territory. The company recently reported Q1 2026 earnings with a revenue beat but EPS miss, secured an acquisition of UK Biocentre Limited, and partnered with Frontier Space for research.
Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) will release its fiscal second quarter 2024 earnings, which concluded on March 31, 2024, after the market closes on Wednesday, May 8, 2024. The company will host a conference call and live webcast on the same day at 4:30 p.m. Eastern Time to discuss these financial results. Interested parties can register online for the call or access the live webcast via the Azenta investor relations website.
GW&K Investment Management LLC Has $32.47 Million Stake in Azenta, Inc. $AZTA
GW&K Investment Management LLC has reduced its stake in Azenta, Inc. by 9.7% in Q3, now holding 1,130,471 shares valued at $32.47 million, while institutional investors collectively own about 99.08% of the company. Azenta's board authorized a $250 million share buyback program, indicating internal confidence in the stock's value. Analysts are divided on Azenta, with a consensus "Hold" rating and an average price target of $41.33, significantly higher than its recent trading price of approximately $24.79.
Osborne Clarke advises shareholders of UK Biocentre on sale to Azenta Life Sciences
Osborne Clarke advised the shareholders of UK Biocentre Limited on its sale to Azenta UK Ltd, a subsidiary of Azenta, Inc. UK Biocentre, a leading provider of sample management and storage services, will continue to operate under its existing name and serve as Azenta’s European operational hub. This acquisition is expected to accelerate innovation and investment in the life sciences and healthcare sector.
Azenta: £20.5 Million Acquisition Of UK Biocentre To Expand European Biorepository Capabilities
Azenta, a life sciences solutions company, has acquired UK Biocentre Limited for £20.5 million to expand its European biorepository capabilities. This acquisition strengthens Azenta's sample management solutions, provides a European operational hub, and will support the rollout of its BioArc Ultra automated storage platform. Despite a slight initial dilution to adjusted EBITDA, Azenta expects positive revenue growth and margin expansion starting in 2027.
Fisher Asset Management LLC Sells 48,408 Shares of Azenta, Inc. $AZTA
Fisher Asset Management LLC reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 7.6% during the third quarter, selling 48,408 shares and now owning 586,289 shares valued at $16.84 million. Other institutional investors have also adjusted their positions in the company, with hedge funds and institutional investors collectively owning 99.08% of the stock. Azenta recently reported quarterly earnings, missing analyst estimates but exceeding revenue expectations, and its board authorized a $250 million stock buyback plan.
Azenta acquires UK Biocentre for £20.5 million
Azenta Inc. has acquired UK Biocentre Limited for £20.5 million, a move expected to establish UK Biocentre as Azenta's European operational hub, expanding its sample management and processing services. Despite a projected short-term dilution to 2026 Adjusted EBITDA margin, the acquisition is anticipated to boost organic revenue growth and EBITDA margin expansion in 2027 and 2028. This strategic acquisition positions Azenta centrally within the life sciences ecosystem, complementing their existing German biorepository and building on recent financial reports and partnerships.
Azenta to Acquire UK Biocentre for GBP 20.5 Million to Build European SRS Hub
Azenta has announced the acquisition of UK Biocentre for GBP 20.5 million, including contingent consideration. This strategic move aims to strengthen Azenta’s Sample Repository Services (SRS) presence in Europe, with UK Biocentre slated to become a key European hub. The acquisition will expand Azenta's capacity in sample management, storage, and high-throughput processing across the continent.
Azenta (AZTA) acquires UK Biocentre in GBP 20.5m European hub deal
Azenta, Inc. (AZTA) has acquired UK Biocentre Limited for GBP 20.5 million, strengthening its European presence in sample management and biorepository services. UK Biocentre, which generated GBP 15.3 million in revenue in the last fiscal year, will serve as Azenta’s European hub for Sample Repository Services. The acquisition is expected to be slightly dilutive to Azenta's 2026 Adjusted EBITDA margin but accretive to organic revenue growth and Adjusted EBITDA margin targets in 2027 and 2028.
Vanguard Group Inc. Lowers Holdings in Azenta, Inc. $AZTA
Vanguard Group Inc. reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 2.7% in the third quarter, selling 123,522 shares but still owning 4,439,358 shares valued at $127.5 million. Other hedge funds also adjusted their positions in AZTA, with some increasing and others decreasing their holdings. Azenta reported mixed financial results, missing EPS estimates but exceeding revenue expectations, and announced a $250 million share repurchase program.
Royce & Associates LP Has $9.88 Million Position in Azenta, Inc. $AZTA
Royce & Associates LP significantly reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 49.0% in the third quarter, now holding 343,934 shares valued at $9.88 million. This comes amidst other institutional investors increasing their positions and analysts providing mixed ratings, though the average target price is $41.33. Azenta recently missed earnings estimates but announced a $250 million share buyback program.
Azenta, Inc. (NASDAQ:AZTA) Short Interest Update
Azenta, Inc. (NASDAQ:AZTA) experienced a significant increase of 21.2% in short interest during February, reaching over 5 million shares. Currently, 12.4% of the company's stock is short-sold, with a short-interest ratio of 4.2 days. Analysts have mixed ratings on the stock, with an average target price of $41.33, while institutional investors hold a substantial portion of the shares.
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
Azenta, Inc. (Nasdaq: AZTA) has acquired UK Biocentre Limited for GBP 20.5 million, enhancing its end-to-end sample management solutions and expanding its European presence. This acquisition strengthens Azenta's biorepository capabilities and is expected to be dilutive to 2026 Adjusted EBITDA margin but accretive to organic revenue growth and Adjusted EBITDA margin in 2027 and 2028. UK Biocentre will serve as a major European operational hub, supporting pharmaceutical, biotechnology, academic, and public health customers.
Azenta stock hits 52-week low at 23.88 USD
Azenta Inc.'s stock has fallen to a 52-week low of $23.99, down 40.78% over the past year and 8.3% in the last week. InvestingPro analysis suggests the stock is oversold and potentially undervalued. The company recently missed Q1 2026 EPS forecasts but exceeded revenue, leading TD Cowen to lower its price target while maintaining a Hold rating.
3 Reasons AZTA is Risky and 1 Stock to Buy Instead
Azenta Inc. (AZTA) shares have significantly underperformed the S&P 500, with analysts pointing to declining revenue, decreasing EPS, and persistent cash burn as major concerns. The article advises against purchasing AZTA stock due to its poor long-term financial performance and recommends investors look for more promising opportunities, such as the suggested "Strong Momentum" stocks, including historical examples like Nvidia and Exlservice.
Azenta, Inc. (NASDAQ:AZTA) Given Average Rating of "Hold" by Brokerages
Eight brokerages have assigned Azenta, Inc. (NASDAQ:AZTA) an average rating of "Hold," with a consensus one-year price target of $41.3333. The company recently reported quarterly earnings, missing analyst estimates on EPS but exceeding revenue forecasts, and announced a stock buyback program of $250 million. Institutional investors have actively traded AZTA shares, and the company specializes in life sciences technology, including sample management and genomic services.
AZTA SEC Filings - Azenta Inc 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Azenta (AZTA) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, offering detailed insights into the company's financial performance, governance, and executive compensation. Recent filings highlight insider transactions, such as sales related to RSU vesting and CFO Lawrence Lin's open-market purchase, as well as the company's quarterly earnings report. Stock Titan offers AI-powered summaries to help investors quickly parse these documents and understand key disclosures.
Azenta schedules Raymond James investor talk with 4 p.m. webcast
Azenta (Nasdaq: AZTA) is set to participate in the Raymond James 47th Annual Institutional Investor Conference on March 3, 2026. The company's management will deliver a presentation starting at 4:00 p.m. ET, which will be accessible via a live webcast on Azenta's investor relations website, with a replay available afterward. This event provides an opportunity for investors to learn about Azenta's strategy, recent financial results, and capital allocation plans.
AZTA Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Azenta Inc (AZTA) for fiscal year 2025, including income statements, balance sheets, and cash flow data, alongside key financial ratios and health signals. It highlights the company's revenue growth, profitability, leverage, liquidity, and cash flow, revealing a neutral Piotroski F-Score and mixed earnings quality. The report is based on SEC filings and offers both annual and quarterly metrics for analysis.
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
Azenta, Inc. (Nasdaq: AZTA) announced its management will participate in the Raymond James 47th Annual Institutional Investor Conference on March 3rd, 2026. A live webcast of their presentation will be available via the company's investor relations website, with a replay accessible afterward. The company specializes in life sciences solutions, providing cold-chain sample management and multiomics services globally.
Azenta, Inc. (AZTA) Investor Outlook: Exploring a 37.95% Potential Upside in the Healthcare Sector
Azenta, Inc. (AZTA) is highlighted as a prominent healthcare sector player with a significant potential upside of 37.95%. The company, formerly Brooks Automation, Inc., has rebranded to focus on life sciences, specializing in sample management and multiomics. Despite recent stock dips, analysts maintain a positive outlook, citing a robust free cash flow and strategic partnerships, including one with Frontier Space Ltd, as drivers for future growth within the life sciences industry.
KeyBanc reiterates Sector Weight on Azenta stock after conference By Investing.com
KeyBanc has reiterated a Sector Weight rating on Azenta, Inc. (NASDAQ:AZTA) following the Society for Laboratory Automation and Screening 2026 Conference, noting positive signals for the life science sector despite the stock's 36.97% decline over the past year. The company recently showcased its BioArc Ultra automated storage system and reported mixed Q1 2026 earnings with a revenue beat but an EPS miss, prompting TD Cowen to lower its price target. Azenta is also advancing space research through a partnership with Frontier Space.
KeyBanc reiterates Sector Weight on Azenta stock after conference
KeyBanc has reiterated a Sector Weight rating on Azenta, Inc. following positive signals for the life science sector observed at a recent conference, despite the stock's 36.97% decline over the past year. The company showcased its BioArc Ultra automated storage system at a sold-out pre-conference event. Recent financial results showed an EPS miss but a revenue beat for Q1 2026, leading TD Cowen to lower its price target due to declining gross margins, while Azenta also partnered with Frontier Space for the EGGS-2 mission.
Azenta to Participate in the Stephens Annual Investment Conferen
Azenta, Inc. (Nasdaq: AZTA) announced its management will participate in the Stephens Annual Investment Conference in Nashville, Tennessee, on November 15-16, 2023. The company will host a presentation on November 16, 2023, at 11:00 am CT, with a live webcast available on its investor relations website. Azenta is a global provider of life sciences solutions, offering cold-chain sample management and multiomics services for drug development and clinical research.
Caprock Group LLC Invests $1.64 Million in Azenta, Inc. $AZTA
Caprock Group LLC has acquired a new stake of 53,707 shares in Azenta, Inc. (NASDAQ:AZTA) valued at approximately $1.64 million during the third quarter, representing 0.12% ownership. Azenta's board has also authorized a $250 million share buyback program, indicating management's view that the stock may be undervalued despite missing consensus on its latest EPS report. Analysts currently have an average "Hold" rating on Azenta with a price target of $41.33.
AlphaQuest LLC Decreases Stake in Azenta, Inc. $AZTA
AlphaQuest LLC significantly reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 91.8% in Q3, selling 47,738 shares and retaining 4,240 shares valued at $122,000. This comes as Azenta missed EPS expectations but exceeded revenue forecasts in its latest quarter, while analysts generally rate the stock as "Hold" with a consensus price target of $41.33. The company has also authorized a $250 million share buyback program.
Azenta’s Space Trials Put Sample Tools And Valuation In New Focus
Azenta, Inc. (NasdaqGS:AZTA) has partnered with Frontier Space to test its sample management technologies in microgravity for space-based life sciences research. This collaboration could validate Azenta's solutions for demanding environments and provide new reference points for biopharma, academic, and government customers. Investors are watching how this high-profile testing ground, along with the company's valuation metrics, will impact its future earnings and market position.
The Top 5 Analyst Questions From Azenta's Q4 Earnings Call
Azenta's Q4 earnings call revealed flat sales, with revenue slightly above estimates but non-GAAP profit and adjusted EBITDA missing expectations, leading to a negative market response. CEO John Marotta acknowledged ongoing operational challenges, including quality issues and macroeconomic headwinds, describing the quarter as transitional. Analysts focused on margin recovery, second-half acceleration, near-term revenue, U.S. academic markets, and the permanence of automated store quality remediations.
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
Azenta Life Sciences has announced a strategic partnership with Frontier Space to advance space-based life sciences research. This collaboration aims to leverage microgravity for scientific discovery and innovation, including participation in the EGGS-2 mission with Orbital Paradigm to test Frontier's SpaceLab Mk 2 research platform. The news highlights Azenta's commitment to cutting-edge research in a unique environment.
Azenta partners with Frontier Space to advance space research
Azenta, Inc. has announced a strategic partnership with Frontier Space to conduct scientific experiments in microgravity environments, including participation in the EGGS-2 mission. The collaboration utilizes Azenta’s specialized FluidX 0.26mL tubes for secure transport of experimental samples and focuses on evaluating thermal management capabilities for life sciences research in space. Despite this advancement, Azenta recently reported a miss on EPS forecasts but exceeded revenue expectations for Q1 2026, leading TD Cowen to revise its price target to $30 from $39 with a Hold rating.
How Azenta's lab tubes are being tested for life science in space
Azenta Life Sciences has partnered with Frontier Space to test its FluidX 0.26mL sample tubes in microgravity aboard the EGGS-2 mission, launched in January 2026. This collaboration aims to evaluate the tubes' durability and the SpaceLab Mk 2 platform's thermal management capabilities in space, extending Azenta's sample management technology into new research environments. The initiative is a strategic step for both companies to advance space-based life sciences research and biomanufacturing.
Azenta stock hits 52-week high at $28.44 despite yearly decline
Azenta Inc. stock recently reached a 52-week high of $28.44, yet it has experienced a 45.11% decline over the past year. Despite being in oversold territory and trading below its Fair Value with a strong balance sheet, the company reported a miss on EPS forecasts but exceeded revenue expectations in its first-quarter 2026 earnings. Analysts have adjusted price targets due to lower gross margins, highlighting the stock's volatility for investors.
Azenta, Inc. SEC 10-Q Report
Azenta, Inc. released its Q3 Form 10-Q report, showing revenue growth driven by the Multiomics segment, despite a net loss of $15.4 million. The company's strategic focus involves optimizing operations and divesting the B Medical Systems business to concentrate on core Sample Management Solutions and Multiomics segments. Azenta aims to enhance profitability and product offerings while maintaining a global presence and employing approximately 3,000 workers.
Azenta (NASDAQ:AZTA) Downgraded to "Hold" Rating by Wall Street Zen
Wall Street Zen has downgraded Azenta (NASDAQ:AZTA) from a "buy" to a "hold" rating, aligning with MarketBeat's consensus "Hold" rating and an average target price of $41.33. This downgrade follows Azenta's recent quarterly earnings, where it reported $0.09 EPS, missing estimates by $0.02, though revenue slightly exceeded expectations. Despite the downgrade, Azenta's board authorized a $250 million stock buyback program, signaling management's belief that the stock may be undervalued.
Azenta, Inc. (NASDAQ:AZTA) Q1 2026 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA) announced its Q1 2026 earnings, reporting $0.09 EPS, missing expectations of $0.11. The company's organic revenue declined by approximately 1% year-over-year, largely due to cautious capital spending and government funding uncertainties. Despite this, Azenta reaffirmed its full-year 2026 guidance for 3% to 5% organic revenue growth and about 300 basis points of adjusted EBITDA margin expansion, anticipating a stronger second half as growth initiatives gain traction and quality issues in automated stores are resolved.
Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation
Azenta, Inc. (AZTA), formerly Brooks Automation, has undergone a significant transformation from a semiconductor automation company to a pure-play life sciences firm focused on cold chain sample management and multiomics. Despite a strong, debt-free balance sheet, the company faces scrutiny due to recent operational challenges and missed earnings targets after its Q1 2026 results. The article explores whether Azenta's critical role in biobanking infrastructure makes it a long-term value investment, contingent on its ability to execute its "Sample-to-Insight" strategy and improve profit margins.
Stocks making big moves yesterday: Azenta, FTAI Aviation, Reddit, Columbia Sportswear, and RenaissanceRe
This article details the stock movements of several companies yesterday. Azenta, FTAI Aviation, and Reddit experienced declines due to mixed earnings, profit-taking, and investor concerns over AI competition, respectively. Columbia Sportswear and RenaissanceRe saw their stocks rise after reporting better-than-expected fourth-quarter results and providing encouraging forecasts.
